Biomni envisions artificial intelligence augmenting human scientists and accelerating discovery by interpreting multi-modal datasets, optimizing protein stability, orchestrating wet-lab instruments, and generating experimentally testable protocols.
Abstract
Biomedical research is increasingly constrained by repetitive, fragmented workflows that slow discovery. We introduce Biomni, a general-purpose biomedical artificial intelligence agent that autonomously executes diverse research tasks. To map the biomedical action space, Biomni's action-discovery agent mines tools, databases, and protocols from thousands of publications across 25 domains, building a unified agentic environment. Its general-purpose architecture integrates large language model reasoning with retrieval-augmented planning and code-based execution, dynamically composing workflows without predefined templates. Systematic benchmarking shows strong generalization across heterogeneous tasks-causal gene prioritization, drug repurposing, rare-disease diagnosis, microbiome analysis, and molecular cloning-without task-specific tuning. Real-world case studies demonstrate Biomni interpreting multi-modal datasets, optimizing protein stability, orchestrating wet-lab instruments, and generating experimentally testable protocols. Biomni envisions artificial intelligence augmenting human scientists and accelerating discovery.
In the use case in drug repurposing for Alzheimer’s Disease, EcoXAI evaluated 103 drug candidates and identified 79 novel candidates whose predictive models exceeded a randomized baseline, including the CCR5 antagonist Maraviroc, whose generated hypothesis was subsequently supported by the literature.
Nicholas Matsumoto, Hyunjun Choi, P. Freda et al.· bioRxiv· 0 citations
Automation is transforming scientific discovery by enabling systematic exploration of complex hypotheses. Large language models (LLMs) perform well across diverse tasks and promise to accelerate research, but often struggle with logical structures. Here, we present a framework for biological discovery integrating LLM-b...
Daniel Brunnsåker, Alexander H. Gower, Prajakta Naval et al.· Journal of the Royal Society...· 2 citations
Evidence is synthesised on agentic AI and LLMs applied to precision medicine, encompassing drug discovery, genomics, oncology, rare disease diagnostics and clinical pharmacology, which examines architectural components, recent validation milestones and emerging challenges.
Fabricio F. Costa· Drug Discovery Today· 0 citations
It is argued that agentic bioinformatics should be assessed through workflow correctness rather than final-answer correctness alone, and the Function--Evidence--Validation (FEV) framework is introduced, which separates demonstrated workflow operations, traceable support for actions and claims, and use-case-specific val...
This article examines the emerging paradigm of agentic AI for scientific discovery, traces the conceptual shift from tools to agents, lays out a six-stage workflow spanning literature synthesis to manuscript generation, and reviews practical systems in chemistry, equation discovery, materials science, and general machi...
Alexander Taktakidze· Longevity Horizon· 1 citation
It is concluded that effective use of agentic AI requires both domain expertise to frame questions and evaluate outputs, and coding literacy to guide the AI's approach, while outlining future opportunities for agentic AI workflow to advance the environmental health sciences.
E. Seto· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.